# Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease

> **NCT00239564** · PHASE1,PHASE2 · COMPLETED · sponsor: **Impax Laboratories, LLC** · enrollment: 12 (actual)

## Conditions studied

- Idiopathic Parkinson's Disease

## Interventions

- **DRUG:** IPX054 100 mg
- **DRUG:** IPX054 150 mg
- **DRUG:** IPX054 200 mg
- **DRUG:** IPX054 250 mg
- **DRUG:** IPX054 300 mg

## Key facts

- **NCT ID:** NCT00239564
- **Lead sponsor:** Impax Laboratories, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00239564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00239564, "Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00239564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*